ImmunityBio (IBRX) is moving higher as traders rotate back into the name on renewed optimism around ANKTIVA’s international expansion and near-term medical-meeting visibility. Comments highlighting “unstoppable” global expansion and plans to present new comparative ANKTIVA data at the upcoming American Urological Association (AUA) Annual Meeting have helped lift sentiment into today’s session. (stocktwits.com)

The upbeat tone around commercialization has been competing with a regulatory headline that pressured the stock earlier this spring: ImmunityBio disclosed FDA correspondence tied to promotional/advertising compliance and said it was reaffirming its commitment to compliant communications. That backdrop has made incremental “execution” signals—commercial footprint, conference data, and demand narrative—especially important for the tape. (ir.immunitybio.com)

Investors are now looking ahead to the AUA 2026 window (May 15–18, 2026) for new ANKTIVA-related disclosures and to the company’s next earnings report, which is expected before the market opens on May 11, 2026. Any updates on international launches/partners, label-expansion timelines, and U.S. regulatory interactions could quickly reset near-term expectations. (ir.immunitybio.com)

Today’s gain looks driven more by improving sentiment and catalyst positioning than by a single definitive filing or approval. The bull case is strengthening global commercialization momentum and new clinical/comparative data; the bear case remains U.S. regulatory/compliance scrutiny and headline risk around legal/regulatory developments.